Peringatan Keamanan

Patients experiencing an overdose may present with headache, nausea, vomiting, blurred vision, dilated pupils, dizziness, dry mouth, difficulty swallowing, CNS stimulation, as well as hot, dry skin.L7967 Treat patients with gastric lavage, emetics, activated charcoal, sedatives for excitement, and a cholinergic agent if indicated.L7967

The oral LD50 in mice is 625mg/kg.L7967

Dicyclomine

DB00804

small molecule approved

Deskripsi

Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.A6556,A182555,A234659,L7967 Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.L7982

Dicyclomine was granted FDA approval on 11 May 1950.L7967

Struktur Molekul 2D

Berat 309.4867
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean plasma elimination half life is approximately 1.8 hours.[A182525,L7967]
Volume Distribusi The volume of distribution for a 20mg oral dose is 3.65L/kg.[L7967]
Klirens (Clearance) Data regarding the clearance of dicyclomine is not readily available.[L7967]

Absorpsi

The bioavailability of dicyclomine has not been determined,A182534 though it is likely well absorbed as the primary route of elimination is in the urine.A182525,L7967 Dicyclomine has a Tmax of 1-1.5h.L7967

Metabolisme

The metabolism of dicyclomine has not been well researched.A182525

Rute Eliminasi

Dicyclomine is 79.5% eliminated in the urine and 8.4% in the feces.A182525,L7967

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Alcohol may increase drowsiness caused by dicyclomine.
  • 2. Drink plenty of fluids. Dicyclomine may reduce sweating, increasing the risk of overheating in warm weather or during exercise.

Interaksi Obat

1144 Data
Aclidinium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Dicyclomine.
Mirabegron The risk or severity of urinary retention can be increased when Dicyclomine is combined with Mirabegron.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dicyclomine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Dicyclomine.
Tiotropium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Dicyclomine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type A.
Glucagon Dicyclomine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Dicyclomine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Dicyclomine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Dicyclomine is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Dicyclomine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.
Hydromorphone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.
Oxycodone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alfentanil.
Nalbuphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Dicyclomine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Dicyclomine is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Dicyclomine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Dicyclomine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Dicyclomine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Dicyclomine is combined with Carfentanil, C-11.
Codeine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.
Meperidine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Meperidine.
Fentanyl The risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.
Benzhydrocodone The risk or severity of adverse effects can be increased when Dicyclomine is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Dicyclomine.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dicyclomine.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Dicyclomine.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Dicyclomine.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Dicyclomine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Dicyclomine.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dicyclomine.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Dicyclomine.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Dicyclomine.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Dicyclomine.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Dicyclomine.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Dicyclomine.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Dicyclomine.
Tropicamide The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tropicamide.
Cocaine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Cocaine.
Methantheline The risk or severity of adverse effects can be increased when Dicyclomine is combined with Methantheline.
Cycrimine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Cycrimine.
Cyclopentolate The risk or severity of adverse effects can be increased when Dicyclomine is combined with Cyclopentolate.
Oxybutynin The risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.
Pentolinium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan.
Diphenidol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenidol.
Fenoterol The risk or severity of adverse effects can be increased when Dicyclomine is combined with Fenoterol.
Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione.
Solifenacin The risk or severity of adverse effects can be increased when Dicyclomine is combined with Solifenacin.
Isopropamide The risk or severity of adverse effects can be increased when Dicyclomine is combined with Isopropamide.
Mepenzolate The risk or severity of adverse effects can be increased when Dicyclomine is combined with Mepenzolate.
Hexocyclium The risk or severity of adverse effects can be increased when Dicyclomine is combined with Hexocyclium.
Dimetindene The risk or severity of adverse effects can be increased when Dicyclomine is combined with Dimetindene.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M2 CHRM2

Referensi & Sumber

Synthesis reference: Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.
Artikel (PubMed)
  • PMID: -
    Danhof I, Schreiber E, Wiggans D, Leyland H: Metabolic dynamics of dicyclomine hydrochloride in man as influenced by various dose schedules and formulations Toxicology and Applied Pharmacology. 1967 Dec 18;13(1):16-23.
  • PMID: 3597632
    Walker BJ, Lang JF, Okerholm RA: Quantitative analysis of dicyclomine in human plasma by capillary gas chromatography and nitrogen-selective detection. J Chromatogr. 1987 Apr 24;416(1):150-3. doi: 10.1016/0378-4347(87)80496-6.
  • PMID: 9059856
    Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol. 1997 Feb 12;320(2-3):209-14.
  • PMID: 14254329
    MCGRATH WR, LEWIS RE, KUHN WL: THE DUAL MODE OF THE ANTISPASMODIC EFFECT OF DICYCLOMINE HYDROCHLORIDE. J Pharmacol Exp Ther. 1964 Dec;146:354-8.
  • PMID: 3612532
    Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA: Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther. 1987 Jul;242(1):257-62.

Contoh Produk & Brand

Produk: 280 • International brands: 6
Produk
  • Bentyl
    Tablet • 20.6 mg/1 • Oral • US • Approved
  • Bentyl
    Syrup • 10 mg/5mL • Oral • US • Approved
  • Bentyl
    Capsule • 10 mg/1 • Oral • US • Approved
  • Bentyl
    Tablet • 20.6 mg/1 • Oral • US • Approved
  • Bentyl
    Injection, solution • 20 mg/2mL • Intramuscular • US • Approved
  • Bentyl
    Injection, solution • 20 mg/2mL • Intramuscular • US • Approved
  • Bentylol
    Syrup • 10 mg / 5 mL • Oral • Canada • Approved
  • Bentylol Dospan 30mg
    Tablet, extended release • 30 mg / tab • Oral • Canada • Approved
Menampilkan 8 dari 280 produk.
International Brands
  • Byclomine
  • Di-Spaz
  • Dibent
  • Dilomine
  • Dyspas — Savage
  • Merbentyl — Sanofi

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul